Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Identification of a Titin-Derived HLA-A1–Presented Peptide as a Cross-Reactive Target for Engineered MAGE A3–Directed T Cells

7 Aug 2013

Abstract excerpt

MAGE A3, which belongs to the family of cancer-testis antigens, is an attractive target for adoptive therapy given its reactivation in various tumors and limited expression in normal tissues. We developed an affinity-enhanced T cell receptor (TCR) directed to a human leukocyte antigen (HLA)-A*01-restricted MAGE A3 antigen (EVDPIGHLY) for use in adoptive therapy. Extensive preclinical investigations revealed no...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Immunotherapy and Immune Responses
Share to Virus-based gene therapy research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 23926201
DOI: 10.1126/scitranslmed.3006034

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identification of a Titin-Derived HLA-A1–Presented Peptide as a Cross-Reactive Target for Engineered MAGE A3–Directed T CellsPMID 23926201Read ↗

Direct molecular mimicry enables off-target cardiovascular toxicity by an enhanced affinity TCR designed for cancer immunotherapy.Semantic proximity Read ↗

Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma.Semantic proximity Read ↗

A systematic safety pipeline for selection of T-cell receptors to enter clinical useSemantic proximity Read ↗

T-cell-receptor cross-recognition and strategies to select safe T-cell receptors for clinical translationSemantic proximity Read ↗

Targeting peptide antigens using a multiallelic MHC I-binding system.Semantic proximity Read ↗

TCRs with Distinct Specificity Profiles Use Different Binding Modes to Engage an Identical Peptide–HLA ComplexSemantic proximity Read ↗

Development of an affinity-enhanced clinical candidate TCR targeting NY-ESO-1 with optimal potency and high specificitySemantic proximity Read ↗

EpiTox: A Multi-Modular Framework for Population-Aware Off-Target Prediction Highlighting MAGEA3 Cross-ReactivitySemantic proximity Read ↗

TCR Gene Transfer: MAGE-C2/HLA-A2 and MAGE-A3/HLA-DP4 Epitopes as Melanoma-Specific Immune TargetsSemantic proximity Read ↗

Targeting the recurrent Rac1P29S neoepitope in melanoma with heterologous high-affinity T cell receptorsSemantic proximity Read ↗

A phage display selected Fab fragment with MHC class I-restricted specificity for MAGE-A1 allows for retargeting of primary human T lymphocytesSemantic proximity Read ↗

Subtle affinity-enhancing mutations in a myelin oligodendrocyte glycoprotein-specific TCR alter specificity and generate new self-reactivity.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.